Current Studies - Allergy

Open Label Icatibant home study in Hereditary Angioedema (IRB# 38489)

Status: Active

 

Investigators:

  • Timothy Craig, D.O., Division of Pulmonary, Allergy and Critical Care Medicine

 

Description:

Open-Label, Multicenter Study to Evaluate Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema.

 

Locations:

Penn State Milton S. Hershey Medical Center

 

Contacts:

Study director: Timothy Craig, D.O.

For more information: call Crystal Rhoads, 717-531-4513

 

Categories:

  • HAE